Skip to content

Study · Randomized controlled trial · 2026

2 results

One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.

Holt J, Sandsdal RM, Byberg S, Janus C, Juhl CR, Jørgensen JR, Hartmann B, Stallknecht B, Holst JJ, Madsbad S, Jensen SBK, Torekov SS

Obesity (Silver Spring, Md.)25 Sept 2025Cited by 8 (Europe PMC)

PMID40998556 (opens in a new tab)PMCIDPMC12724041 (opens in a new tab)DOI10.1002/oby.70043 (opens in a new tab)PepBankPUB-40998556
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity after weight loss, liraglutide treatment did not change late-phase postprandial GLP-1 response versus placebo.

    In plain wordsIn adults with obesity after weight loss, liraglutide did not change the measured post-meal GLP-1 response versus placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeLate-phase postprandial GLP-1 response
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    3.0 mg/day · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Late-phase postprandial GLP-1 response was unchanged in both groups treated with GLP-1 receptor agonist compared to placebo.
    2 context sentences
    Summary · context
    This study is an exploratory analysis of adults with obesity (n = 195) who lost 13.1 kg on a low-calorie diet and were randomized to 52 weeks of either usual activity, moderate-to-vigorous intensity exercise, the GLP-1 receptor agonist liraglutide (3.0 mg/day), or the combination.
    Summary · context
    The primary endpoint was change in late-phase GLP-1 response to a 3-h liquid mixed meal test before and after diet-induced weight loss and after 1 year of intervention.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with obesity after weight loss, the liraglutide-exercise combination did not change late-phase postprandial GLP-1 response versus placebo.

    In plain wordsIn adults with obesity after weight loss, the liraglutide-exercise combination did not change the measured post-meal GLP-1 response versus placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeLate-phase postprandial GLP-1 response
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Hormone levels · Endocrine and hormones

    Source sentences

    Summary
    Late-phase postprandial GLP-1 response was unchanged in both groups treated with GLP-1 receptor agonist compared to placebo.
    2 context sentences
    Summary · context
    This study is an exploratory analysis of adults with obesity (n = 195) who lost 13.1 kg on a low-calorie diet and were randomized to 52 weeks of either usual activity, moderate-to-vigorous intensity exercise, the GLP-1 receptor agonist liraglutide (3.0 mg/day), or the combination.
    Summary · context
    The primary endpoint was change in late-phase GLP-1 response to a 3-h liquid mixed meal test before and after diet-induced weight loss and after 1 year of intervention.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT04122716

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Signe Torekovn = 215Sept 2016 to est. Nov 2021

Obesity

Trial pageClinicalTrials.govUpdated 2 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.